Loading
Life sciences · Journal article
Frontiers in Oncology · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Tumor-associated macrophages (TAMs) are abundant and functionally diverse components of the lung tumor microenvironment (TME) and are associated with therapeutic response and resistance in non-small cell lung cancer (NSCLC). Durable responses to immune checkpoint inhibitors (ICIs) and targeted therapies remain limited, with TAM-associated immune evasion and therapy-refractory microenvironments representing potentially relevant components of this resistance landscape. This narrative review prioritizes evidence from human NSCLC specimens and clinically annotated cohorts, especially from single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics, while integrating relevant mechanistic evidence from NSCLC experimental systems, animal models, and related cancer contexts. Moving beyond the M1/M2 paradigm, we synthesize convergent findings to describe recurring, niche-resolved TAM programs. Across NSCLC, we highlight recurrent SPP1 -associated, TREM2 -associated, and C1q/LAM-like macrophage programs as a practical framework for integrating recurrent TAM states across spatial and treatment contexts. We propose an integrative framework in which TAM state dynamics are associated with, and may contribute to, therapy-refractory phenotypes during (i) ICI therapy through immune exclusion, (ii) oncogene-targeted therapy through macrophage-associated bypass signaling and survival plasticity, particularly in EGFR-TKI resistance, and (iii) post-radiochemotherapy microenvironmental remodeling, with potential implications for residual disease ecosystems that require further clinical validation, particularly with respect to recurrence and relapse. TAM program signatures and spatial organization provide a rationale for investigating biomarker-guided stratification and macrophage-directed combination strategies targeting state–niche axes. Future work should prioritize clinically validated, state- and niche-resolved multimodal biomarkers and prospective translational studies to support rational pairing with ICIs and targeted therapies.